KRAS G13C选择性抑制揭示 codon 13突变癌症对野生型RAS亚型的依赖增加
本研究报道口服RAS(ON) G13C选择性共价三复合物抑制剂RMC-8839在部分KRAS G13C突变异种移植模型中诱导肿瘤消退,但三分之一的KRAS G13C突变人癌细胞系体外显示RAS通路抑制不完全。Codon 13突变RAS稳定性降低、核苷酸交换增加且GTP水解增强,致癌性减弱,且常伴野生型RAS激活突变。RMC-8839与RAS(ON)多选择性抑制剂联用较单药更深抑制肿瘤生长。
要点
- RMC-8839在部分KRAS G13C突变异种移植模型中诱导肿瘤消退
- 三分之一KRAS G13C突变细胞系体外RAS通路抑制不完全
- RMC-8839联合RAS(ON)多选择性抑制剂较单药更深抑制肿瘤生长
核心结论
- KRAS G13C突变癌症对野生型RAS(ON)信号依赖增加,联合RAS(ON)多选择性抑制剂可增强疗效。
研究设计与样本
- 临床前研究:使用KRAS G13C突变异种移植模型和人癌细胞系评估RMC-8839及联合RAS(ON)多选择性抑制剂的疗效与通路抑制。
主要发现
- RMC-8839在部分KRAS G13C突变异种移植模型中诱导肿瘤消退。
- 三分之一的KRAS G13C突变人癌细胞系体外显示RAS通路抑制不完全,尽管KRAS G13C近完全结合。
- Codon 13突变RAS稳定性降低、核苷酸交换增加、内在及GAP刺激的GTP水解增强,致癌性减弱。
- Codon 13突变肿瘤中富集导致野生型RAS激活增加的共发RAS通路突变。
- RMC-8839联合RAS(ON)多选择性抑制剂较任一单药更深抑制KRAS G13C突变异种移植肿瘤生长。
临床怎么用
- KRAS G13C突变癌症可能需联合RAS(ON)多选择性抑制剂以克服野生型RAS代偿。
局限性
- 研究为临床前体外和异种移植模型,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Covalent KRAS G12C inhibitors have changed the treatment landscape for NSCLC and CRC patients, but numerous RAS-mutant cancers lack approved targeted therapies. Here we describe RMC-8839, an oral RAS(ON) G13C-selective, covalent, tri-complex inhibitor that induced tumor regressions in selected KRAS G13C-mutant xenograft models. However, one-third of KRAS G13C-mutant human cancer cell lines in vitro showed incomplete RAS pathway suppression despite near-complete KRAS G13C engagement, suggesting a role for wild-type RAS(ON). We find that codon 13-mutant RAS differs from other KRAS mutations, exhibiting decreased stability, increased nucleotide exchange, and substantial intrinsic and GAP-stimulated GTP hydrolysis, which decreases oncogenicity. Furthermore, co-occurring RAS pathway mutations leading to increased wild-type RAS activation are enriched in codon 13 mutant tumors. Consistent with a role for wild-type RAS(ON) signaling, combination of RMC-8839 with a RAS(ON) multi-selective inhibitor resulted in deeper inhibition of KRAS G13C-mutant xenograft tumor growth than either inhibitor alone.
引用
- Seamon KJ, Zhuang Y, Yang YC, et al. Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers. Cancer Discov. 2026. PMID: 42329095. doi:10.1158/2159-8290.CD-25-0886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。